2020-11-03T09:34:01-06:00 2019-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2019-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC % LINDA JENSEN CFO AMER 5714831300 2318 MILL ROAD Suite 800 ALEXANDRIA VA 22314 LINDA JENSEN CFO 5714831300 2020-11-02 true Marc Berger P01871563 7038930600 73.53.153.141 54621820203085000005 2020-11-03 P F80C4C4CE64063363A32333BB37C43EAD2BBFD59 F80C4C4CE64063363A32333BB37C43EAD2BBFD59 2019 2021-01-29 14:40:06Z CLIFFORD HUDIS MD CEO 2318 MILL ROAD 800 ALEXANDRIA VA 22314 164682134 false X WWW.ASCO.ORG X 1964 NY ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY AND EQUITABLE PATIENT CARE. 18 18 564 2981 22759889 7625514 8575801 7525300 136574903 145628204 11398200 6514346 3335190 3043571 159884094 162711421 1168748 2492264 0 0 59231331 61964764 0 0 3350660 85406395 83651841 145806474 148108869 14077620 14602552 227652015 269484782 118594943 131909947 109057072 137574835 X SEE SCHEDULE O false false 45034199 622505 75048988 SCIENTIFIC AND MEDICAL EDUCATION: SEE SCHEDULE O 39058114 5000 23830960 QUALITY OF CARE: SEE SCHEDULE O 14973319 57500 32305592 EDUCATIONAL PUBLICATIONS: SEE SCHEDULE O 35073915 1767383 14442664 134139547 true true false true false false false false false false true false false false true true false true false true true true true false false false false true false true true false false false false false false false false false false false false false false true true true true false false true 464 0 true 564 true true true false false false false false false false false false false false X 18 18 false false true false true true true true true false false true true true true true true true true false CA NY VA X LINDA JENSEN CFO 5714831300 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 X Clifford HudisMD CEO, NON-VOTING DIRECTOR 36.0 1.5 X 898194 0 24233 Dina Michels Esq EVP, CHIEF LEGAL OFFICER 36.0 1.5 X 581731 0 39055 Richard Schilsky MD EVP, Chief Medical Officer 37.5 0.0 X 576789 0 37756 Bernie Khoo VP, INFORMATION TECHNOLOGY 37.5 0.0 X 429423 0 43541 CORY WIEGERT EVP, CEO CANCERLINQ 37.5 0.0 X 414423 0 47574 Linda Jensen MBA EVP, Chief Financial Officer 36.0 1.5 X 401924 0 38536 Stephen Grubbs MD VP, Clinical Affairs 37.5 0.0 X 391923 0 37756 Nancy Daly MS MPH EVP, CHIEF PHILANTHROPIC OFF. 3.0 34.5 X 387673 0 38537 Jamie Von Roenn MD VP, Education 37.5 0.0 X 392173 0 31472 Robert Miller MD MEDICAL DIRECTOR, CANCERLINQ 37.5 0.0 X 362119 0 43811 CARMEN JACKSON COO, CANCERLINQ 37.5 0.0 X 314738 0 43811 Deborah Kamin RN PHD VP, POLICY AND ADVOCACY 37.5 0.0 X 307923 0 38537 Kristin Ludwig VP, MKTG. & Communications 36.5 1.0 X 306192 0 24233 ANIL NAIR CTO, CANCERLINQ 37.5 0.0 X 291546 0 36301 DAVID SAMPSON VP, JOURNALS & PUBLISHER 37.5 0.0 X 281211 0 43321 CAROLYN WHITEHEAD DIVISION DIR., CONQUER CANCER 1.0 36.5 X 294412 0 22524 Krista Barnes VP, Member Services 37.5 0.0 X 257496 0 41475 Amanda Davis-Aitken VP, Meeting Services 37.5 0.0 X 255192 0 28656 CHRISTOPHER MERLAN EVP, CHIEF DIGITAL OFFICER 37.5 0.0 X 145269 0 9338 BLASE N POLITE MD M BOARD MEMBER 1.0 0.0 X 3625 0 0 MICHAEL A THOMPSON M BOARD MEMBER 1.0 0.0 X 2500 0 0 Bruce Johnson MD PAST President - PARTIAL YEAR 1.0 0.0 X X 0 0 0 Monica Bertagnolli MD President/Chair 1.0 0.0 X X 0 0 0 Peter Adamson MD Board Member 1.0 0.0 X 0 0 0 Stephen B Edge MD Board Member 1.0 0.0 X 0 0 0 Maha HussainMD Board Member 1.0 0.0 X 0 0 0 J Chris Nunnink MD Board Member 1.0 0.0 X 0 0 0 Reshma Jagsi MD Dphi Board Member 1.0 0.0 X 0 0 0 Michael KostyMD Board Member 1.0 0.0 X 0 0 0 Eric Small MD Board Member 1.0 0.0 X 0 0 0 Jedd Wolchok MD PHD Board Member 1.0 0.0 X 0 0 0 HOWARD A BURRIS III PRESIDENT-ELECT/President 1.0 0.0 X X 0 0 0 LAURIE GASPAR MDMBA TREASURER 1.0 0.0 X X 0 0 0 A WILLIAM BLACKSTOCK BOARD MEMBER 1.0 0.0 X 0 0 0 LEE ELLIS MD FACS BOARD MEMBER 1.0 0.0 X 0 0 0 TONY SHU KAM MOK MD BOARD MEMBER 1.0 0.0 X 0 0 0 JAAP VERWEIJ MD PHD BOARD MEMBER 1.0 0.0 X 0 0 0 TRACEY WEISBERG MD BOARD MEMBER 1.0 0.0 X 0 0 0 Lori J Pierce MD President Elect 1.0 0.0 X X 0 0 0 ELIZABETH A MITTENDOR BOARD MEMBER 1.0 0.0 X 0 0 0 ETHAN M BASCH MD BOARD MEMBER 1.0 0.0 X 0 0 0 7296476 0 670467 184 false true false TEMPUS LABS 600 WEST CHICAGO AVE CHICAGO IL 60654 DATA CURATION SVC 3773700 SPARGO INC PO 828795 PHILADELPHIA PA 191828795 EVENT PLANNING SVC 2970147 AMAZON WEB SERVICE PO BOX 84023 SEATTLE WA 981248423 CLOUD COMPUTING SVC 2559170 FREEMAN DECORATING PO BOX 660613 DALLAS TX 725660613 EVENT PLANNING SVC 2405197 DARTMOUTH PRINTING COMPANY PO BOX 419817 BOSTON MA 022419817 PRINTING SERVICE 1998136 76 7525300 7525300 DUES 900099 7155214 7155214 EDUCATIONAL MEETINGS & PRODUCTS 900099 75048988 69127504 5921484 EDUCATIONAL PUBLICATIONS 511190 32305592 17052037 15253555 QUALITY 900099 23830960 22843799 987161 MEMBER RELATIONS & INFORMATION 900099 349049 349049 6938401 6938401 145628204 6066749 6066749 0 2543846 2543846 582855 334215 248640 0 248640 248640 2084095 1636498 447597 447597 447597 0 0 0 0 0 0 0 0 0 MAILING LIST 251085 251085 251085 162711421 123116955 22759889 9309277 X 2287513 2287513 0 204751 204751 0 6438819 3119741 3120419 198659 0 44563815 41232294 3331521 2993232 2808746 184486 4213614 3915784 297830 3755284 3463551 291733 0 533024 528619 4405 183472 2375 181097 290516 290516 0 79584 79584 27897419 27728640 168445 334 585630 582672 2958 2529096 2318566 210530 8595316 8299877 294845 594 0 3014972 2931523 83449 6468203 6221588 245542 1073 0 14272170 13818850 453320 2651464 2092645 558819 0 3037458 2410091 627367 687702 209558 478144 PRINTING & PRODUCTION 4834824 4833353 1471 DEVELOPMENT FEE TO RELATED ORG 3150000 0 0 3150000 UBI TAX 1251310 1250935 375 0 POSTAGE & SHIPPING 1211639 1209927 1712 0 2378042 2377432 610 148108869 134139547 10618662 3350660 0 0 10106685 18722737 0 0 16453791 26850085 0 0 0 0 0 0 0 0 7481194 7946486 78793752 30659003 49050243 48134749 142567125 167830725 1992977 0 0 0 0 0 0 0 227652015 269484782 17199923 18849700 0 0 31345157 37609894 38400000 38400000 0 0 0 0 0 0 0 0 31649863 37050353 118594943 131909947 X 109057072 136574835 0 1000000 109057072 137574835 227652015 269484782 X 14602552 16856803 -2941592 X false true X true false X 13960857 11941446 9978694 8575801 7525300 51982098 88958786 78719498 93297144 136574903 123116955 520667286 0 0 0 102919643 90660944 103275838 145150704 130642255 572649384 13914277 11641675 9856323 8575801 7525300 51513376 0 13914277 11641675 9856323 8575801 7525300 51513376 521136008 6401944 5651063 5969247 7763043 8610595 34395892 0 6401944 5651063 5969247 7763043 8610595 34395892 3133751 3414649 2871782 4855029 7776132 22051343 306781 277776 248859 255345 251085 1339846 112762119 100004432 112365726 158024121 147280067 630436465 0.82663 0.81649 0.05456 0.05400 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 263 439341 439604 133699943 134139547 1000000 250000 1000000 1000000 1000000 1000000 4000000 6000000 259559 291378 198306 439604 1188847 250000 250000 250000 250000 1000000 1500000 3346 2905 1947 263 8461 7342677 7342677 48003287 14507866 33495421 773776 637110 136666 2471905 1626244 845661 20202107 13887783 6314324 48134749 0 LIABILITY UNDER INTEREST RATE SWAP 13303010 TAXABLE BOND PAYABLE 16377714 DUE TO RELATED ORGANIZATION 7369629 37050353 X 176881263 16856803 -2941592 13915211 162966052 79584 -334215 -254631 162711421 148363500 334215 334215 148029285 79584 79584 148108869 PART X, LINE 2 IN ACCORDANCE WITH GAAP, THE ORGANIZATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WILL BE SUSTAINED ON EXAMINATION BY TAXING AUTHORITIES, BASED ON TECHNICAL MERITS OF THE POSITION. THE TAX BENEFITS RECOGNIZED IN THE CONSOLIDATED FINANCIAL STATEMENTS FROM SUCH A POSITION ARE MEASURED BASED ON THE LARGEST BENEFIT THAT HAS A GREATER THAN 50% LIKELIHOOD OF BEING REALIZED UPON ULTIMATE SETTLEMENT. THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. GENERALLY, THE ORGANIZATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS PRIOR TO DECEMBER 31, 2016. PART XI, LINE 2D LOSS ON INTEREST RATE SWAP ($2,941,592) PART XI, LINE 4B RENTAL EXPENSES -$334,215 PART XII, LINE 2D RENTAL EXPENSES $334,215 true East Asia and the Pacific Program Services SCIENTIFIC MEETING 1825415 East Asia and the Pacific Program Services OUTREACH & EDUCATIONAL 177409 Europe (Including Iceland and Greenland) Program Services OUTREACH & EDUCATIONAL 89694 North America 0 5 Program Services OUTREACH & EDUCATIONAL 63319 Russia and the Newly Independent States Program Services OUTREACH & EDUCATIONAL 68983 South America Program Services OUTREACH & EDUCATIONAL 265111 South Asia Program Services OUTREACH & EDUCATIONAL 740704 Sub-Saharan Africa Program Services OUTREACH & EDUCATIONAL 790191 Europe (Including Iceland and Greenland) Grantmaking 106522 Central America and the Caribbean Grantmaking 2212 East Asia and the Pacific Grantmaking 24731 North America Grantmaking 5045 South America Grantmaking 8563 South Asia Grantmaking 27926 Middle East and North Africa Grantmaking 1000 Russia and the Newly Independent States Grantmaking 2228 Sub-Saharan Africa Grantmaking 26524 Central America and the Caribbean Program Services OUTREACH & EDUCATIONAL 68466 0 5 0 5 4225577 68466 4294043 Europe (Including Iceland and Greenland) CONTRIBUTION 79625 WIRE Europe (Including Iceland and Greenland) CONTRIBUTION 18000 WIRE 2 idea award Central America and the Caribbean 1 1320 WIRE 892 Travel Book idea award East Asia and the Pacific 2 2625 WIRE 3106 travel book idea award Europe (Including Iceland and Greenland) 1 1480 WIRE 1417 travel book idea award North America 1 1320 WIRE 725 travel book idea award Russia and the Newly Independent States 1 1320 WIRE 908 travel book idea award South America 3 3960 WIRE 4603 travel book idea award South Asia 8 11025 WIRE 12901 travel book idea award Sub-Saharan Africa 7 10200 WIRE 15324 travel book Breakthrough Award East Asia and the Pacific 19 19000 WIRE Breakthrough Award Europe (Including Iceland and Greenland) 6 6000 WIRE Breakthrough Award Middle East and North Africa 1 1000 WIRE Breakthrough Award North America 3 3000 WIRE Breakthough Award South Asia 4 4000 WIRE Breakthrough Award Sub-Saharan Africa 1 1000 WIRE true false false false false true SCHEDULE F, PART I, LINE 1 INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS (IDEA) - THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS PROVIDE SUPPORT FOR EARLY-CAREER ONCOLOGISTS IN DEVELOPING COUNTRIES TO LEARN ABOUT ONCOLOGY CARE AND RESEARCH BY ESTABLISHING STRONG RELATIONSHIPS WITH LEADING ASCO ONCOLOGISTS WHO SERVE AS SCIENTIFIC MENTORS TO EACH RECIPIENT. RECIPIENTS LEARN ABOUT QUALITY CANCER CARE AND RESEARCH BY ATTENDING THE ASCO ANNUAL MEETING AND VISITING THEIR MENTOR'S CANCER CENTER IN THE UNITED STATES AND CANADA. RECIPIENTS ARE EXPECTED TO SHARE THE KNOWLEDGE AND TRAINING THEY RECEIVE THROUGH THE PROGRAM WITH COLLEAGUES IN THEIR HOME COUNTRIES ONCE THEY RETURN. IDEAS ARE PROVIDED TO RECIPIENTS BASED ON MERIT THROUGH A PEER REVIEW PROCESS USING ESTABLISHED ELIGIBILITY CRITERIA. IDEA RECIPIENTS ARE REQUIRED TO AGREE TO TERMS AND CONDITIONS APPLICABLE TO THE IDEA, ARE REQUIRED TO COMMUNICATE WITH THEIR MENTORS, TO ATTEND ALL IDEA-RELATED EVENTS, TO SUBMIT EVALUATIONS AFTER THE ANNUAL MEETING AND MENTOR SITE VISIT, AND TO SUBMIT ONE-YEAR REPORTS. BREAKTHROUGH SUMMIT AND MERIT AWARDS These awards recognize oncology fellows, junior faculty, and trainees for their valuable research in clinical cancer treatment and technology innovations in cancer care. Awardees presented their research at the inaugural ASCO Breakthrough: A Global Summit for Oncology meeting held during October 11-13, 2019, in Bangkok, Thailand. Abstract Awards supported the first authors of the 50 highest-rated abstracts selected for presentation at the ASCO Breakthrough Summit. Merit Awards recognized the quality and scientific merit of research submitted by oncology fellows and trainees to an ASCO meeting. true Conquer Cancer Foundation of ASCO 2318 Mill Rd Ste 800 Alexandria VA 22314 311667995 501(c)(3) 1764000 Contribution Banner Health 2901 N Central Ave Phoenix AZ 85012 450233470 501(c)(3) 60000 Contribution Brigham & Women's Hospital 75 Francis St Tower 1 Boston MA 02215 042312909 501(c)(3) 167500 Contribution Dana Farber Cancer Institute 450 Brookline Avenue Boston MA 02215 042263040 501(c)(3) 25000 Contribution Duke University Medical Center 2424 Erwin Rd Suite 601 Durham NC 27705 560532129 501(c)(3) 6667 Contribution Friends of Cancer Research 1800 M Street NW Washington DC 20036 521983273 501(c)(3) 32000 Contribution Regents of the University of Michigan 300 N Ingalls St Ann Arbor MI 48109 386006309 501(C)(3) 40000 contribution Susan G Komen Foundation 5005 LBJ Freeway Ste 250 Dallas TX 75244 751835298 501(c)(3) 10000 Contribution SARAH CANNON RESEARCH INSTITUTE ONE PARK PLAZA NASHVILLE FL 32703 201557751 LLC 109166 CONTRIBUTION Health Volunteers Oversees 1900 L Street NW Washington DC 20036 521485477 501(c)(3) 10000 CONTRIBUTION National Coalition for Cancer Survivorship 8455 Colesville Rd Silver Springs MD 20910 850357897 501(c)(3) 10000 CONTRIBUTION 10 1 SCHEDULE I, PART I, LINE 1 ASCO provides assistance to 501(c)(3) organizations that serve the cancer community. SCHEDULE I, PART I, LINE 2 ASCO PROVIDES ASSISTANCE TO ORGANIZATIONS THAT SERVE THE CANCER CARE COMMUNITY. THE MAJORITY OF THESE GRANTS ARE MADE TO OTHER 501(C)(3) ORGANIZATIONS. THE GRANT MADE TO A NON-501(C)(3) ORGANIZATION WAS MADE PURSUANT TO A WRITTEN AGREEMENT THAT REQUIRED THE GRANT FUNDS TO BE USED FOR SPECIFIC EDUCATIONAL AND CHARITABLE PROJECTS, THAT THE GRANTEE RETURN ANY PORTION OF THE GRANT FUNDS THAT WERE NOT USED FOR SUCH PROJECTS, AND THAT THE GRANTEE PROVIDE ANNUAL NARRATIVE AND FINANCIAL REPORTS TO ASCO REGARDING GRANTEE'S USE OF THE GRANT FUNDS. X X X X X X false false false false false false false true false Clifford HudisMD CEO, NON-VOTING DIRECTOR 818627 0 79567 0 0 0 21000 0 3233 0 922427 0 0 0 Richard Schilsky MD EVP, Chief Medical Officer 569039 0 7500 0 250 0 21000 0 16756 0 614545 0 0 0 Dina Michels Esq EVP, CHIEF LEGAL OFFICER 574231 0 7500 0 0 0 21000 0 18055 0 620786 0 0 0 Linda Jensen MBA EVP, Chief Financial Officer 394424 0 7500 0 0 0 21000 0 17536 0 440460 0 0 0 Nancy Daly MS MPH EVP, CHIEF PHILANTHROPIC OFF. 380173 0 7500 0 0 0 21000 0 17537 0 426210 0 0 0 Jamie Von Roenn MD VP, Education 384423 0 7500 0 250 0 21000 0 10472 0 423645 0 0 0 Bernie Khoo VP, INFORMATION TECHNOLOGY 424423 0 5000 0 0 0 21000 0 22541 0 472964 0 0 0 Stephen Grubbs MD VP, Clinical Affairs 384423 0 7500 0 0 0 21000 0 16756 0 429679 0 0 0 Robert Miller MD MEDICAL DIRECTOR, CANCERLINQ 355869 0 6000 0 250 0 21000 0 22811 0 405930 0 0 0 Deborah Kamin RN PHD VP, POLICY AND ADVOCACY 299423 0 7500 0 1000 0 21000 0 17537 0 346460 0 0 0 Kristin Ludwig VP, MKTG. & Communications 298692 0 7500 0 0 0 21000 0 3233 0 330425 0 0 0 Krista Barnes VP, Member Services 249746 0 7500 0 250 0 18664 0 22811 0 298971 0 0 0 Amanda Davis-Aitken VP, Meeting Services 247692 0 7500 0 0 0 18577 0 10079 0 283848 0 0 0 CORY WIEGERT EVP, CEO CANCERLINQ 414423 0 0 0 0 0 28618 0 18956 0 461997 0 0 0 CARMEN JACKSON COO, CANCERLINQ 280288 0 34200 0 250 0 21000 0 22811 0 358549 0 0 0 ANIL NAIR CTO, CANCERLINQ 270096 0 21200 0 250 0 20257 0 16044 0 327847 0 0 0 DAVID SAMPSON VP, JOURNALS & PUBLISHER 273461 0 7500 0 250 0 20510 0 22811 0 324532 0 0 0 CHRISTOPHER MERLAN EVP, CHIEF DIGITAL OFFICER 115269 0 20000 0 10000 0 0 0 9338 0 154607 0 0 0 CAROLYN WHITEHEAD DIVISION DIR., CONQUER CANCER 257212 0 37200 0 0 0 19291 0 3233 0 316936 0 0 0 Part I, Line 7: PERFORMANCE-BASED BONUS PAYMENTS CAN BE MADE TO SOME EMPLOYEES LISTED ON SCHEDULE J AND INCLUDED AS PART OF THE TOTAL COMPENSATION. THE BONUS PAYMENTS ARE NOT ON A FIXED BASIS BUT RATHER ARE BASED ON PERFORMANCE AND DETERMINED BY THE CEO WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. A INDUSTRIAL DEVELOPMENT AUTHORITYCITY OF ALEXANDRI 521381432 01530lad2 2012-08-01 38400000 Buy/Buildout 5 floors HQ building false false false A 0 0 38400000 0 0 0 0 0 0 38400000 0 0 2008 true false true true A false false true true false 0 0.04590 0.04590 false false false true A false false false true true true FMS WERTMANAGEMENT 30. false false false 0 true A true PART IV, QUESTION 3 ASCO HAS AN INTEREST RATE SWAP AGREEMENT WITH FMS WERTMANAGEMENTBANK THROUGH 2038. ASCO MAKES FIXED INTEREST PAYMENTS AT A 3.587% RATE. VARIABLE SWAP PAYMENTS, BASED ON ONE-MONTH LIBOR, RECEIVED FROM THE SWAP COUNTERPARTY ARE USED TO MAKE THE VARIABLE INTEREST PAYMENTS AS THEY COME DUE. THIS INTEREST RATE SWAP AGREEMENT QUALIFIES AS A DERIVATIVE INSTRUMENT AND IS USED TO MITIGATE THE EFFECT OF INTEREST RATE FLUCTUATIONS. PART VI, QUESTION 2C THE LATEST REBATE COMPUTATION DATE FOR THE REPORTED BOND ISSUE WAS OCTOBER 2, 2019. FORM 990, PART III, LINE 1 ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY AND EQUITABLE PATIENT CARE. ASCO'S VISION IS A WORLD WHERE CANCER IS PREVENTED OR CURED, AND EVERY SURVIVOR IS HEALTHY. ASCO PROMOTES AND PROVIDES FOR: - LIFELONG LEARNING FOR ONCOLOGY PROFESSIONALS, - CANCER RESEARCH, - AN IMPROVED ENVIRONMENT FOR ONCOLOGY PRACTICE, - ACCESS TO QUALITY CANCER CARE, - A GLOBAL NETWORK OF ONCOLOGY EXPERTISE, AND - EDUCATED AND INFORMED PATIENTS WITH CANCER. FORM 990, PART III, LINE 4A SCIENTIFIC AND MEDICAL EDUCATION: ASCO PROVIDES SCIENTIFIC AND EDUCATIONAL PROGRAMS AND CONTENT ON A BROAD RANGE OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS LIVE MEETINGS ON THE LATEST RESEARCH AND ADVANCES IN THE FIELD OF CLINICAL ONCOLOGY. THE ONCOLOGY-SPECIFIC INFORMATION PRESENTED AT THESE MEETINGS ENHANCES KNOWLEDGE ABOUT TREATING CANCER AND CARING FOR CANCER PATIENTS. THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER SCIENTIFIC AND EDUCATIONAL MEETING IN THE ONCOLOGY COMMUNITY. THE THEMATIC MEETINGS, PRESENTED OR CO-SPONSORED BY ASCO, PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC SESSIONS ON SPECIFIC TYPES OF CANCERS. ASCO'S PROGRAMS ARE DESIGNED TO SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE TO ASSIST THEM IN DELIVERING HIGH QUALITY CANCER CARE AND CONDUCTING CLINICAL RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. PROGRAMS ADDRESS THE MODERN-DAY PRACTICE OF ONCOLOGY FOR ALL LEVELS OF PRACTITIONERS INCLUDING ONCOLOGY FELLOWS, JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, ETC. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS, IMPLEMENTS AND EVALUATES CONTINUING MEDICAL EDUCATION (CME) TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS AND OTHER MEMBERS OF THE CANCER CARE TEAM TO ENABLE THEM TO BETTER MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY, ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CME FOR ASCO'S CME PROGRAM. ASCO MAKES MUCH OF THE CONTENT FROM ITS MEETINGS AND OTHER EDUCATIONAL AND SCIENTIFIC CONTENT PUBLICLY AVAILABLE THROUGH TWO ASCO WEBSITES: WWW.ASCO.ORG AND WWW.CANCER.NET. ADDITIONALLY, ASCO MAKES SCIENTIFIC AND EDUCATIONAL MATERIALS AVAILABLE THROUGH A VARIETY OF CHANNELS, INCLUDING BOOKS, DVDS, VIRTUAL MEETINGS, PODCASTS AND PUBLIC FORUMS. HIGHLIGHTS OF THE 2019 ACTIVITIES INCLUDE: OVER 42,500 PEOPLE ATTENDED THE 2019 ASCO ANNUAL MEETING, INCLUDING PHYSICIANS, NURSES, CAREGIVERS, PATIENTS, AND PATIENT ADVOCATES. APPROXIMATELY 40% OF THE ATTENDEES AT THE 2019 ASCO ANNUAL MEETING WERE INTERNATIONAL ATTENDEES. THE 2019 ANNUAL MEETING FEATURED OVER 265 EDUCATIONAL AND SCIENTIFIC SESSIONS AND OVER 5,000 ABSTRACTS WERE PRESENTED OR PUBLISHED. NEARLY 5,000 PRESENTATIONS WERE CAPTURED IN AUDIO AND VIDEO TO BE MADE AVAILABLE ELECTRONICALLY. IN ADDITION TO THE ASCO ANNUAL MEETING, ASCO SPONSORS OR CO-SPONSORS MORE THAN 40 EDUCATIONAL AND SCIENTIFIC SYMPOSIA, WORKSHOPS, AND COURSES INSIDE AND OUTSIDE THE UNITED STATES ON A WIDE VARIETY OF CANCER-RELATED TOPICS TO IMPROVE ONCOLOGY CARE WORLDWIDE. THESE MEETINGS INCLUDE: - BEST OF ASCO - PALLIATIVE AND SUPPORTIVE CARE IN ONCOLOGY SYMPOSIUM - QUALITY CARE SYMPOSIUM - GASTROINTESTINAL (GI) CANCERS SYMPOSIUM - GENITOURINARY (GU) CANCERS SYMPOSIUM - CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM INTERNATIONAL AFFAIRS MEETINGS AND COURSES: - ASCO BREAKTHROUGH - BEST OF ASCO INTERNATIONAL - JOINT SYMPOSIA - ADVANCED CANCER COURSES - MULTIDISCIPLINARY CANCER MANAGEMENT COURSES ASCO PUBLISHES DAILY NEWS PRODUCTS FOR EACH OF ITS MAJOR MEETINGS (E.G.,ASCO ANNUAL MEETING, GI CANCERS SYMOSIUM, GU CANCERS SYMOSIUM). THESE PRODUCTS INCLUDE PRINT NEWSPAPERS THAT ARE DISTRIBUTED ONSITE TO ALL ATTENDEES AND PUBLICLY AVAILABLE ONLINE. THE DAILY NEWS PRODUCTS PROVIDE EDITORIAL COVERAGE OF KEY MEETING SESSIONS, COMMENTARIES BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND OTHER TOPICS OF INTEREST TO ASCO MEMBERS AND MEETING ATTENDEES FROM AROUND THE WORLD. FORM 990, PART III, LINE 4B QUALITY OF CARE: ASCO PRODUCES EVIDENCE-BASED GUIDELINES, DEVELOPS AND VALIDATES QUALITY MEASURES IN ONCOLOGY, AND CONDUCTS QUALITY MEASUREMENT, IMPROVEMENT, AND CERTIFICATION ACTIVITIES PROGRAMS INCLUDE: - CANCERLINQ. THIS BIG-DATA PLATFORM DELIVERS VALUABLE INSIGHTS AND TOOLS TO IMPROVE PATIENT CARE BY COLLECTING AND ANALYZING REAL-WORLD CANCER DATA FROM HEALTHCARE IT SYSTEMS ACROSS THE COUNTY. THE CANCERLINQ DATABASE REFLECTS CANCER CARE IN ALL ITS REAL-WORLD VARIABILITY - ALLOWING CLINICIANS TO LEARN FROM THE EXPERIENCE OF EVERY PATIENT. - QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES: QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. QOPI CERTIFICATION PROGRAM. THE QOPI CERTIFICATION PROGRAM PROVIDES A THREE-YEAR CERTIFICATE RECOGNIZING HIGH QUALITY CARE FOR OUTPATIENT HEMATOLOGY-ONCOLOGY PRACTICES. THE CERTIFICATION PROCESS CREATES A CULTURE OF EXCELLENCE AND SELF-EXAMINATION THAT HELPS PRACTICES DELIVER THE BEST CARE TO THEIR PATIENTS - CLINICAL PRACTICE GUIDELINES AND UPDATES. ASCO HAS PUBLISHED MORE THAN 50 PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. - QOPI REPORTING REGISTRY. ASCO PROVIDES A QUALIFIED CLINICAL DATA REGISTRY TO HELP MEMBERS SATISFY THE FEDERAL GOVERNMENTS MIPS REPORTING REQUIREMENTS. - QUALITY TRAINING PROGRAM. ASCOS QUALITY TRAINING PROGRAM IS DESIGNED TO HELP PRACTICES IMPROVE CLINICAL CARE AND OPERATIONAL PERFORMANCE. IN ADDITION, ASCO OFFERS PRACTICE MANAGEMENT PROGRAMS AND PRODUCTS DESIGNED TO SUPPORT PRACTICE HEALTH TO ENABLE PRACTICES TO DELIVER HIGH QUALITY CARE. THESE RESOURCES INCLUDE: - PRACTICE.NET. THIS LEARNING NETWORK IS FOCUSED ON HELPING PRACTICES IMPROVE THEIR BUSINESS OPERATIONS - FDA ALERTS. ASCO PARTNERS WITH THE FDA TO PROVIDE ITS MEMBERS TIMELY SAFETY ALERTS AND NOTICES OF NEWLY APPROVED CANCER THERAPIES. - PRACTICE EVALUATION. ASCO PROVIDES BOTH OPERATIONAL AND CLINICAL EVALUATION SERVICES INCLUDING READINESS AND PRACTICE OPERATIONS ASSESSMENTS, ANALYTICS, TRIAGE PATHWAYS, NURSE TRAINING SUPPORT, AND A VALUE BASED CARE DELIVERY MODEL. FORM 990, PART III, LINE 4C SCIENTIFIC PUBLICATIONS: ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. o ASCO PUBLISHES SEVERAL PEER-REVIEWED SCIENTIFIC JOURNALS: o JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED, PEER-REVIEWED JOURNAL THAT DISSEMINATES QUALITY ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. o JCO ONCOLOGY PRACTICE (JCO OP) INCLUDES ORIGINAL RESEARCH AND PERSPECTIVES ON CLINICAL AND ADMINISTRATIVE MANAGEMENT ADDRESSING THE PRACTICE OF ONCOLOGY, WHICH ARE EDITED BY ONCOLOGISTS. o JCO GLOBAL ONCOLOGY (JCO GO) IS AN ONLINE ONLY, OPEN ACCESS JOURNAL FOCUSED ON CANCER CARE, RESEARCH AND CARE DELIVERY ISSUES UNIQUE TO COUNTRIES AND SETTINGS WITH LIMITED HEALTHCARE RESOURCES. o JCO CLINICAL CANCER INFORMATICS (JCO CCI) IS AN ONLINE-ONLY INTERDISCIPLINARY JOURNAL PUBLISHING CLINICALLY RELEVANT RESEARCH BASED ON BIOMEDICAL INFORMATICS METHODS AND PROCESSES APPLIED TO CANCER-RELATED DATA, INFORMATION AND IMAGES. o JCO PRECISION ONCOLOGY (JCO PO) IS A PEER-REVIEWED, ONLINE-ONLY, ARTICLE BASED JOURNAL PUBLISHING ORIGINAL RESEARCH, REPORTS, OPINIONS AND REVIEWS THAT ADVANCE THE SCIENCE AND PRACTICE OF PRECISION ONCOLOGY AND DEFINE GENOMICS-DRIVEN CLINICAL CARE OF PATIENTS WITH CANCER. ASCO PUBLISHES THE ANNUAL CLINICAL CANCER ADVANCES (CCA) REPORT. THIS PUBLICLY-AVAILABLE REPORT ESTABLISHES THE MOST IMPORTANT CLINICAL ADVANCES IN ONCOLOGY EACH YEAR. THE REPORT SERVES TO DOCUMENT THE PROGRESS BEING MADE AGAINST CANCER THROUGH CLINICAL RESEARCH, PARTICULARLY THROUGH FEDERALLY FUNDED RESEARCH. ASCO IS INVOLVED IN THE PRODUCTION OF THE ASCO POST, A TRADE PUBLICATION. WHILE NOT OWNED OR PUBLISHED BY ASCO, THIS TRADE COVERS NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY AND ASCO PROVIDES ASCO-SPECIFIC CONTENT FOR INCLUSION. FORM 990, PART III, LINE 4D MEMBER SERVICES: ASCO WORKS TO SUPPORT AND EDUCATE ITS MORE THAN 45,000 MEMBERS THROUGH ITS DAILY ACTIVITIES, INCLUDING PROCESSING NEW MEMBERSHIP APPLICATIONS AND MEMBER DUES, PHONE AND EMAIL COMMUNICATIONS, RESEARCHING AND FULFILLING MEMBER REQUESTS, MAINTAINING THE INTEGRITY OF MEMBER DATA, AND NEW MEMBER RECRUITMENT AND RETENTION EFFORTS. ASCO CONNECTION IS THE OFFICIAL MEMBER MAGAZINE FOR AND ABOUT MEMBERS OF ASCO AND THE PRIMARY SOURCE OF INFORMATION ABOUT ASCO'S PROGRAMS AND SERVICES. ALONG WITH ITS COMPANION PROFESSIONAL NETWORKING SITE, ASCOCONNECTION.ORG, ASCO CONNECTION PROMOTES OPPORTUNITIES FOR INTERACTION BETWEEN ASCO AND ITS MEMBERS, AND MEMBERS AND THEIR COLLEAGUES TO FACILITATE THE DISSEMINATION OF INFORMATION RELATING TO CLINICAL RESEARCH, BEST PRACTICES STANDARDS, AND TREATMENT OF PATIENTS. ASCOCONNECTION.ORG FEATURES COMMENTARY BY LEADERS IN THE FIELD, DISCUSSION FORUMS, ONLINE EXCLUSIVES AND COMMENT-ENABLED ARTICLES FROM THE MEMBER MAGAZINE, AS WELL AS OPPORTUNITIES TO CREATE GROUPS. EXPENSES $9,585,095. INCLUDING GRANTS OF $408,333. REVENUE $7,504,263. RESEARCH: ASCO IS ACTIVELY ENGAGED IN THE SUPPORT, PROMOTION AND CONDUCT OF CLINICAL CANCER RESEARCH. RESEARCH RELATED ACTIVITIES INCLUDE: o RESEARCH COMMUNITY FORUM (RCF). ASCO PROVIDES A NETWORK (ONLINE AND IN-PERSON) FOR ALL MEMBERS OF THE ONCOLOGY RESEARCH COMMUNITY TO PROMOTE BEST PRACTICES FOR CONDUCTING AND MANAGING CLINICAL RESEARCH. o ORIGINAL RESEARCH. ASCO CONDUCTS RESEARCH TO DEVELOP EVIDENCE THAT INFORMS PATIENT CARE, PUBLIC POLICY, AND EDUCATION. RESEARCH INCLUDES SURVEYS, OBSERVATIONAL STUDIES AND CLINICAL TRIALS. o TAPUR. ASCO IS CONDUCTING A CLINICAL TRIAL TO TEST THE SAFETY AND EFFICACY OF FDA-APPROVED, TARGETED ANTICANCER DRUGS IN OTHER CANCER TYPES FOR PATIENTS WITH THE SAME GENOMIC ALTERATION. o SCIENTIFIC/RESEARCH COLLABORATIONS. ASCO WORKS WITH OTHER STAKEHOLDERS IN THE COMMUNITY, INCLUDING GOVERNMENT AGENCIES, PATIENT ADVOCACY GROUPS, AND OTHER PROFESSIONAL MEDICAL SOCIETIES TO SUPPORT AND PROMOTE RESEARCH THAT INFORMS EVIDENCE-BASED PATIENT CARE. o ASCO-FDA SCIENTIFIC COLLABORATIONS. ASCO JOINTLY HOSTS PUBLIC WORKSHOPS WITH THE FDA TO PROVIDE STAKEHOLDERS AN OPPORTUNITY TO DISCUSS EMERGING ISSUES IN RESEARCH AND FDA REVIEW OF NEW THERAPIES. o DATA/RESEARCH REQUESTS. ASCO REVIEWS 3RD PARTY REQUESTS TO CONDUCT RESEARCH USING THE SOCIETYS PROPRIETARY ASSETS. RESEARCH GRANTS AND AWARDS. ASCO MAKES GRANTS TO CONQUER CANCER, THE ASCO FOUNDATION, WHICH PROVIDES RESEARCH GRANTS AND AWARDS TO SUPPORT THE INDEPENDENT RESEARCH INITIATIVES OF CLINICAL INVESTIGATORS AT ALL LEVELS OF THEIR CAREERS. EXPENSES $9,003,637. INCLUDING GRANTS OF $1,350,000. REVENUE $5,772,767. CANCER POLICY AND ADVOCACY: ASCOS POLICY AND ADVOCACY WORK FOCUSES ON THE ISSUES OF ACCESS TO AND DELIVERY OF HIGH-QUALITY AND EQUITABLE CANCER CARE FOR CANCER PATIENTS. WORKING WITH VOLUNTEER ASCO MEMBERS, THE SOCIETY ENGAGES WITH THE ADMINISTRATION, CONGRESS, AND STATE LAW MAKERS TO ADDRESSES POLICY ISSUES OF CRITICAL IMPORTANCE TO THE PRACTICE OF ONCOLOGY AND PATIENT CARE. ASCO'S POLICY AND ADVOCACY PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING CLINICAL CANCER RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ASCO PROVIDES EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, ADVOCACY, HOTLINES, TOOLS, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY. ASCO ROUTINLEY COLLABORATES WITH OTHERS IN THE COMMUNITY TO ADVANCE COMMON GOALS RELATED TO ACCESS TO AND DELIVERY OF HIGH-QUALITY CANCER CARE. o STATE/REGIONAL AFFILIATE PROGRAM. THE 46 STATE/REGIONAL AFFILIATES INTERACT WITH ASCO THROUGH THE STATE AFFILIATE COUNCIL, WHERE EACH SOCIETY HAS A VOTING REPRESENTATIVE CHARGED WITH SERVING AS THE BRIDGE BETWEEN THE SOCIETY AND ASCO. AFFILIATES HAVE ACCESS TO A NUMBER OF PROGRAMS INCLUDING STATE SOCIETY MEMBERSHIP RECRUITMENT AND RETENTION ASSISTANCE, LEADERSHIP TRAINING, FEDERAL-LEVEL ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL. ORIGINAL DATA COLLECTION. ASCO CONDUCTS STUDIES AND ANALYSES TO ASSESS THE CURRENT STATE OF ONCOLOGY CARE AND RESEARCH AND DETERMINE THE NEED FOR AND IMPACT OF POLICY CHANGES. EXPENSES $8,361,484. INCLUDING GRANTS OF $9,050. REVENUE $0. PATIENT INFORMATION & OTHER: ASCO PROVIDES IMPORTANT INFORMATION TO THE PUBLIC FREE OF CHARGE THROUGH ITS AWARD-WINNING PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET). CANCER.NET BRINGS THE EXPERTISE AND RESOURCES OF ASCO TO PEOPLE LIVING WITH CANCER AND THOSE WHO CARE FOR AND CARE ABOUT THEM. CANCER.NET PROVIDES ONCOLOGIST-APPROVED INFORMATION TO HELP PATIENTS AND FAMILIES MAKE INFORMED HEALTH CARE DECISIONS. THE SITE OFFERS COMPREHENSIVE GUIDES TO MORE THAN 120 TYPES OF CANCER AND CANCER-RELATED SYNDROMES, INCLUDING DISEASE-SPECIFIC TREATMENT AND SIDE EFFECTS INFORMATION. EXTENSIVE INFORMATION CAN BE FOUND ON NAVIGATING CANCER CARE, COPING WITH CANCER, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, SURVIVORSHIP, AND RESEARCH AND ADVOCACY; SELECT CONTENT IS AVAILABLE IN SPANISH. CANCER.NET ALSO FEATURES VIDEOS, PODCASTS, AND AN AWARD-WINNING BLOG. CANCER.NET MOBILE, ASCOS AWARD-WINNING FREE MOBILE APPLICATION, PROVIDES A FULLY-FEATURED SET OF TOOLS TO HELP PEOPLE MANAGE THEIR CANCER CARE FROM ANYWHERE. CANCER.NET MOBILE IS SPANISH-ENABLED AND INCLUDES KEY FEATURES SUCH AS APPLE HEALTH INTEGRATION (IOS ONLY), MY HEALTH REPORT TO TRACK DATA ENTERED IN THE APP, SYMPTOM AND MEDICATION TRACKER, TOOLS TO RECORD QUESTIONS AND ANSWERS, TRUSTED INFORMATION FROM CANCER.NET, OPTIONAL PASSCODE LOCK, ICLOUD BACKUP, AND MORE. ASCO ALSO OFFERS ASCO ANSWERS PATIENT EDUCATION MATERIALS AVAILABLE IN PRINT AND/OR PDF. ASCO ANSWERS IS A COLLECTION OF ONCOLOGIST-APPROVED PATIENT EDUCATION MATERIALS DEVELOPED BY ASCO FOR PEOPLE WITH CANCER AND THEIR CAREGIVERS. SELECT TITLES ARE AVAILABLE IN SPANISH. ASCO ANSWERS INCLUDE: o GUIDES TO CANCER: THESE COMPREHENSIVE GUIDES HELP NEWLY DIAGNOSED PATIENTS BETTER UNDERSTAND THEIR DISEASE AND TREATMENT OPTIONS. THEY INCLUDE INFORMATION ABOUT DIAGNOSIS, TREATMENT, SIDE EFFECTS, AND PSYCHOSOCIAL EFFECTS AND ALLOW PATIENTS TO RECORD THE SPECIFICS OF THEIR INDIVIDUAL DIAGNOSIS AND TREATMENT PLAN. o FACT SHEETS: FACT SHEETS PROVIDE AN INTRODUCTION TO A SPECIFIC TYPE OF CANCER, CANCER TREATMENT, OR SIDE EFFECT. EACH INCLUDES AN OVERVIEW OF THE SUBJECT, AN ILLUSTRATION, WORDS TO KNOW, AND QUESTIONS TO ASK THE HEALTH CARE TEAM. o TOPIC-SPECIFIC BOOKLETS: THESE BOOKLETS PROVIDE DETAILED INFORMATION FOR PATIENTS AND CAREGIVERS ABOUT PRACTICAL AND SPECIFIC CONCERNS ON TOPICS SUCH AS ADVANCED CANCER CARE PLANNING, MANAGING THE COST OF CANCER CARE, MANAGING CANCER-RELATED PAIN, MANAGING YOUR WEIGHT AFTER A CANCER DIAGNOSIS, PALLIATIVE CARE, AND STOPPING TOBACCO USE AFTER A CANCER DIAGNOSIS. EXPENSES $8,123,700. INCLUDING GRANTS OF $0. REVENUE $1,165,634. FORM 990, PART VI, SECTION A, LINE 1 AS OF DECEMBER 31, 2019, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO ARE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION OF ASCO). DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. PURSUANT TO THE BYLAWS, THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE ARE: THE PRESIDENT, THE PRESIDENT-ELECT, THE CHAIR, THE PAST PRESIDENT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR PRESENT TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 4 IN 2019, THE SOCIETY'S BYLAWS WERE AMENDED TO PROVIDE THAT ASCO MEMBERS WOULD ALSO BE MEMBERS OF THE SAME MEMBERSHIP CLASS OR CLASSES OF THE SOCIETY'S NEWLY ESTABLISHED RELATED 501(C)(6) PROFESSIONAL ORGANIZATION, ASCO ASSOCIATION (D/B/A ASSOCIATION FOR CLINICAL ONCOLOGY). MEMBERS ARE NOW MEMBERS OF BOTH THE SOCIETY AND ITS NEW ASSOCIATION. MEMBERSHIP APPLICATION REVIEW, MEMBER INDUCTION, AND MEMBERSHIP DISCIPLINE AND TERMINATION ARE CONDUCTED SUBJECT TO PROCESSES APPROVED BY BOTH THE SOCIETY'S BOARD OF DIRECTORS AND THE ASSOCIATION'S BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 6 NO ASCO MEMBER IS ENTITLED TO RECEIVE A SHARE OF ASCO'S PROFITS OR EXCESS DUES OR A SHARE OF ASCO'S NET ASSETS UPON DISSOLUTION. THE CATEGORIES OF MEMBERSHIP WITH VOTING RIGHTS AND SPECIFIED RIGHTS ARE AS FOLLOWS: 1. FULL MEMBERS. a. 1.A. FULL MEMBERS ARE (A) EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER (IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR FULL MEMBER STATUS), AND (B) OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G.,EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. b.1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 2. EMERITUS MEMBERS. a.2.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 70, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. b.2.B. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 3. HONORARY MEMBERS. a.3.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. b.3.B. MEMBERS HAVE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE FOR THE ELECTION OF MEMBERS OF THE GOVERNING BODY ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION A, LINE 7B ASCO'S CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED, AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION B, LINE 11 A DRAFT ELECTRONIC COPY OF THE ASCO FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS AND WAS DISCUSSED AT A MEETING OF THE BOARD. AN ELECTRONIC COPY OF THE FINAL FORM WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS, AND WAS REVIEWED BY THE EXECUTIVE VICE PRESIDENT & CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE EXECUTIVE VICE PRESIDENT & CHIEF LEGAL OFFICER PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND CERTAIN FAMILY MEMBERS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER AND WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE CEO OF ASCO'S NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF ASCO (CC); THE CEO OF ASCO'S NON-PROFIT, 501(C)(6) TAX-EXEMPT RELATED ORGANIZATION, ASCO ASSOCIATION (D/B/A ASSOCIATION FOR CLINICAL ONCOLOGY)(ASSOCIATION), THE PRESIDENT OF QOPI CERTIFICATION PROGRAM, LLC; THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF GOVERNORS OF CANCERLINQ LLC. ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2019. THE COMPENSATION OF THE FOLLOWING POSITIONS WERE CONSIDERED AND APPROVED BY THE ASCO BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND AND AN INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE POSITIONS WAS REASONABLE. - SENIOR VICE PRESIDENT & CHIEF LEGAL OFFICER (SVP & CLO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SVP & CLO BASED ON THE ABOVE DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2019. - VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (VP & CFO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP & CFO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2019. - SENIOR VICE PRESIDENT & CHIEF MEDICAL OFFICER (SVP & CMO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SVP & CMO BASED ON THE ABOVE DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2019. - CHIEF DIGITAL OFFICER (CDO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE CDO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2019. - VICE PRESIDENT, INFORMATION TECHNOLOGY (VP, IT): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP, IT BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2017. - EXECUTIVE VICE PRESIDENT & CHIEF PHILANTHROPIC OFFICER OF THE CONQUER CANCER FOUNDATION OF CLINICAL ONCOLOGY (CC): THE EXECUTIVE VICE PRESIDENT & CHIEF PHILANTHROPIC OFFICER OF CC IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EXECUTIVE VICE PRESIDENT & CHIEF PHILANTHROPIC OFFICER OF CC BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2019. - CHIEF EXECUTIVE OFFICER OF CANCERLINQ LLC (CEO OF CLQ): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE CEO OF CLQ BASED ON THE ABOVE DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2019. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S ANNUAL ACCOMPLISHMENTS AND FINANCIAL INFORMATION IS POSTED ON ASCO'S WEBSITE AND AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9 LOSS ON INTEREST RATE SWAP ($2,941,592) FORM 990 PART IX LINE 11G DESCRIPTION:COMMISSIONS TOTAL FEES:6170594 FORM 990 PART IX LINE 11G DESCRIPTION:PUBLIC RELATIONS COORDINATOR TOTAL FEES:1115702 FORM 990 PART IX LINE 11G DESCRIPTION:TEMPORARY STAFF TOTAL FEES:1234733 FORM 990 PART IX LINE 11G DESCRIPTION:CLINICAL TRIAL SITES TOTAL FEES:2509000 FORM 990 PART IX LINE 11G DESCRIPTION:OTHER PROFESSIONAL FEES TOTAL FEES:16867390 QOPI Certification Program LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 271629211 accreditation VA 986911 795305 ASCO ASCO LEASING LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 273378225 RENTAL VA 578110 697022 ASCO CANCERLINQ LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 472315885 QUALITY IMprv VA 65556251 12454729 ASCO CONQUER CANCER FOUNDATION OF ASCO 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 311667995 Grants VA 501(C)(3) 7 asco true ASCO ASSOCIATION 2318 MILL ROAD ALEXANDRIA VA 22314 833561693 MEMBER SERV. VA 501(C)(6) ASCO true true true true false true false false false false true false true true true true false false false false conquer cancer foundation of asco A, J 602493 FMV conquer cancer foundation of asco b 1764000 fmv conquer cancer foundation of asco c 7525300 fmv conquer cancer foundation of asco e 54777714 fmv conquer cancer foundation of asco m 3150000 fmv conquer cancer foundation of asco n 1082077 fmv conquer cancer foundation of asco o 5955791 fmv